Hikma Pharmaceuticals Plc Total Voting Rights (1207Y)
May 02 2023 - 5:53AM
UK Regulatory
TIDMHIK
RNS Number : 1207Y
Hikma Pharmaceuticals Plc
02 May 2023
Hikma Pharmaceuticals PLC
(the Company)
Total Voting Rights and Capital
LONDON, 2 May 2023 - In accordance with section 5.6.1 of the UK
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules (the 'Rules') , Hikma Pharmaceuticals PLC
(LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK)
notifies the market of the following:
As at 30 April 2023, the issued share capital of the Company
comprised of 220,988,500 Ordinary Shares of 10 pence each
('Shares') with voting rights. This figure excludes 12,833,233
Shares held in treasury, which do not have voting rights.
The figure of 220,988,500 may be used by shareholders (and
others with notification obligations) as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Hussein Arkhagha
Chief Counsel and Company
Secretary +44 20 7399 2760
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREANSAESDDEEA
(END) Dow Jones Newswires
May 02, 2023 05:53 ET (09:53 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024